<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82337">
  <stage>Registered</stage>
  <submitdate>11/10/2007</submitdate>
  <approvaldate>1/11/2007</approvaldate>
  <actrnumber>ACTRN12607000565448</actrnumber>
  <trial_identification>
    <studytitle>A study to compare the preference of two contrasting paracetamol formulations in the management of osteoarthritis pain</studytitle>
    <scientifictitle>A study to compare the preference of two contrasting paracetamol formulations in the management of osteoarthritis pain</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the knee</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All patients will receive both treatments. Two weeks treatment with immediate release paracetamol (1000mg four times daily - oral), and two weeks of extended release paracetamol (1330mg three times daily - oral). There is no washout period between the treatments.</interventions>
    <comparator>Immediate release paracetamol (1000mg four times daily - oral) for 2 weeks.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Patient preference for a particular treatment in the management of osteoarthritis pain</outcome>
      <timepoint>When patients have completed both 2 week arms of the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patient satisfaction with treatment using a verbal rating scale.</outcome>
      <timepoint>Completed at the end of each 2 week treatment period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient attitude towards treatment convenience</outcome>
      <timepoint>At the end of the study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Global assessment of response to treatment</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall experience of pain using a verbal rating scale.</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of sleep during the night</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Night time disturbance due to knee pain</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain on waking</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain on walking</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain at rest</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compliance with medication</outcome>
      <timepoint>At the end of each 2 week treatment period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>At least 45 years of age, good general health, diagnosis of osteoarthritis of the knee with the pain worse in one knee, pain must be suitable for treatment with a simple analgesic</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of a secondard cause of osteoarthritis, medical condition that may affect the ability to rate pain, any contraindication to the use of paracetamol or ibuprofen, intra-articular steroid injection to the knees within the last 2 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation</concealment>
    <sequence>The assignment of the order of study medication will be determined by a computer-generated randomisation schedule.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>260</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline Consumer Healthcare</primarysponsorname>
    <primarysponsoraddress>82 Hughes Avenue
Ermington NSW 2072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>GlaxoSmithKline Consumer Healthcare</fundingname>
      <fundingaddress>1500 Littleton Road
Parsippany NJ 07054</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Paracetamol is first-line pain management for osteoarthrits and this study is designed to investigate patient preference for sustained release paracetamol given 3xdaily compared with standard paracetamol tablet given 4xdaily.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>3/10/2007</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Fiona Dunagan</name>
      <address>GSK Consumer Healthcare
82 Hughes Avenue
(Locked Bag 3)
Ermington NSW 2113</address>
      <phone>+61 2 96840888</phone>
      <fax />
      <email>fiona.m.dunagan@gsk.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fiona Dunagan</name>
      <address>GSK Consumer Healthcare
82 Hughes Avenue
(Locked Bag 3)
Ermington NSW 2113</address>
      <phone>+61 2 96840888</phone>
      <fax />
      <email>fiona.m.dunagan@gsk.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>